Results 241 to 250 of about 15,263 (254)

Mechanisms of Dupilumab

Clinical and Experimental Allergy, 2020
Talal Chatila, Hani Harb
exaly  

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Allergy: European Journal of Allergy and Clinical Immunology, 2022
Daphne Bakker, Marjolein De Bruin-Weller, Lotte Spekhorst   +2 more
exaly  

Characterizing dupilumab facial redness: A multi-institution retrospective medical record review

Journal of the American Academy of Dermatology, 2020
Jane Grant-Kels, Steven Brett Sloan, Reid Waldman   +2 more
exaly  

Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Journal of Clinical Medicine, 2022
Emanuele Cozzani, Niccolo Capurro
exaly  

Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review

International Immunopharmacology, 2023
Xiaojing Kang, Yingbing Sang, Yongzhen Hong   +2 more
exaly  

Facial and neck erythema associated with dupilumab treatment: A systematic review

Journal of the American Academy of Dermatology, 2021
Vincent Piguet, Christine E Jo, Jensen Yeung   +2 more
exaly  

Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management

JAAD Case Reports, 2022
exaly  

Dupilumab for treatment of atopic dermatitis

Expert Review of Clinical Pharmacology, 2018
Andreas Wollenberg
exaly  

Dupilumab’s duplicity

Journal of the American Academy of Dermatology
openaire   +2 more sources

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

Allergy: European Journal of Allergy and Clinical Immunology, 2020
Lieneke Fm Ariëns, Edward Knol, Daphne Bakker   +2 more
exaly